President Research And Development
Vectory Therapeutics
AeroLeads people directory · profile
Sander Van Deventer Email & Phone Number
President Research and Development
at
VectorY therapeutics
1 work email found
@vectorytx.com
2 phones found area 135
LinkedIn matched
✓ Verified Jul 2026
4 data sources
Profile completeness 100%
Current company
Role
President Research and Development
Location
Naarden, North Holland, Netherlands
Who is Sander Van Deventer? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Sander Van Deventer is listed as President Research and Development at VectorY therapeutics, based in Naarden, North Holland, Netherlands. AeroLeads shows a work email signal at vectorytx.com, phone signal with area code 135, and a matched LinkedIn profile for Sander Van Deventer.
Sander Van Deventer previously worked as Chief Executive Officer at Vectory and Chief Technology Officer at Vectory. Sander Van Deventer holds Md, Phd, Internal Medicine, Gastroenterology from University Of Amsterdam.
Company email context
Email format at VectorY therapeutics
This section adds company-level context without repeating Sander Van Deventer's masked contact details.
{first}.{last}@vectorytx.com
86% confidence
AeroLeads found 1 current-domain work email signal for Sander Van Deventer. Compare company email patterns before reaching out.
Profile bio
About Sander Van Deventer
I had a critical role in the development of the first commercial monoclonal antibody (Remicade) the first commercial gene therapy in the Western world (Glybera) and multiple gene therapies reaching the clinic clinic for acute intermittent porphyria, lysosomal storage diseases and neurodegenerative diseases. I led the development of Hemgenix (AAV5-FIX) for which the FDA accepted the Biologics License Application for priority review in May 2022, as well as the Huntington silencing program at uniQure. I was one of the founding partners, former Managing Partner and current Operating Partner at Forbion Capital Partners, a venture capital firm investing in the life sciences in Europe and North America. I have more than 20 years experience at boards of private, Euronext- and Nasdaq-listed companies, chairing audit, compensation, nomination and governance committees, and have served as CEO of a Euronext-listed company. I was trained as an internist and board-certified gastroenterologist, received a doctorate of philosophy from the University of Amsterdam, worked as a scientist at Rockefeller University and became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995. In 1998 I co-founded Amsterdam Molecular Therapeutics (AMT; currently Uniqure; NASDAQ: QURE ), a gene therapy company that develops AAV-based gene therapy products. From 2001 until 2004, I chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. I have authored more than 80 book chapters, 600 peer review scientific papers, have organized several large international scientific conferences, and supervised more than 40 PhD students. Bibliographic summary (Google Scholar September 2024: Citations 73407; H-Index: 132).In 2020 I co-founded VectorY Therapeutics, a gene therapy company based in Amsterdam that develops novel AAV vectors delivering molecular binders (VecTabs) and protein degraders (VecTrons) that allow precision targeting of the protein misfolding and aggregation which is central to the pathogenesis of neurodegenerative diseases. VectorY reported preclinical therapeutic activity of VecTabs and VecTrons at several international scientific meetings.I like to cycle (road, gravel, MTB) and I am co-owner of two bicycle shops in the Netherlands.
Listed skills include Lifesciences, Clinical Development, Biotechnology, Cancer, and 46 others.
Current workplace
Sander Van Deventer's current company
Company context helps verify the profile and gives searchers a useful next step.
16 roles
Sander Van Deventer work experience
A career timeline built from the work history available for this profile.
Chief Executive Officer
VectorY Therapeutics a fully integrated gene therapy company based in Amsterdam that develops novel AAV vectors delivering molecular binders that allow precision targeting of protein misfolding and aggregation which is central to the pathogenesis of neurodegenerative diseases.
Chief Technology Officer
VectorY Therapeutics a fully integrated gene therapy company based in Amsterdam that develops novel AAV vectors delivering molecular binders that allow precision targeting of protein misfolding and aggregation which is central to the pathogenesis of neurodegenerative diseases.
Jun 2021 - Nov 2022
Co-Owner Viskercycles
Visker Cycles Haarlem
ViskerCycles is a high-end cycle store: We carry all Specialized road, MTB, cross, gravel, TT and leisure bicycles, as well as the Specialized Turbo MTB, e-bike and speed pedelec models. We also are dealer of Rapha, Thule, Shimano, Muck-Off and GripGrab. Apart from our store in Haarlem, we have a Specialized Test Center in Spaarnwoude and a Giant Test Center in Zoetermeer. We serve Il Magistrale coffee in Van Deventer's Cycles cafe. ViskerCycles organizes regular road and gravel rides and we have a road cycles rental. Check it out on ViskerCycles.cc, LinkedIn or Instagram. Or visit us in one of our stores.
Chief Scientific Officer
Aug 2020 - May 2022
Professor
I am a retired professor of Translational Gastroenterology at LUMC
Sep 2008 - Mar 2021
Executive Vice President Research And Product Development
Led the development of etranacogene dezaparvovec. The U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) of etranacogene dezaparvovec for priority review in May 2022. Led the development of the miQure gene silencing technology that was used in the uniQure Huntington program, as well as the process development allowing AAV manufacturing to scale up to 500 liter bioreactors.
Aug 2019 - Aug 2020
Aug 2017 - Aug 2019
Dec 2006 - 2014
Ceo
Dezima Pharma Bv
I was the founding CEO and subsequently chairman of the scientific advisory board of Dezima Pharma, a company that develops a best-in-class cholesterol-lowering drug. Three years after ir's inception, Dezima Pharma was acquired by Amgen for a total of $1.55m.
Jun 2012 - Mar 2013
Ceo
Led the company towards filing of the Glybera dossier, which became the first gene therapy to obtain market authorization in the Western world. Glybera is a therapy for patients with lipoprotein lipase deficiency, a rare disease that is associated with extremely high plasma triglyceride levels and chylomicrons, resulting in recurrent episodes of potentially fatal pancreatitis.
Jan 2009 - Oct 2009
Cso
Developed a scalable commercial gene therapy platform that resulted in one approved gene therapy and currently 4 additional programs in clinical development
Sep 2004 - Dec 2008
Professor And Chairman Gastroenterology And Hepatology
Built a team of professionals in the area of gastroenterology that became leaders in the field of inflammatory bowel disease, esophageal cancer, pancreatic cancer, colon cancer and therapeutic endoscopy.
Jan 2000 - Sep 2004
Professor And Chairman Experimental Medicine
Built one of the largest and most productive laboratories in the field of inflammation, with major contributions to the development of breakthrough drugs including therapeutic antibodies such as remicade and gene therapies.
Jan 1995 - Jan 2000
Scientist
Dec 1988 - Jan 1991
2 education records
Sander Van Deventer education
Md, Phd, Internal Medicine, Gastroenterology
University Of Amsterdam
Education record
Stedelijk Gymnasium Haarlem
FAQ
Frequently asked questions about Sander Van Deventer
Quick answers generated from the profile data available on this page.
What company does Sander Van Deventer work for?
Sander Van Deventer works for VectorY therapeutics.
What is Sander Van Deventer's role at VectorY therapeutics?
Sander Van Deventer is listed as President Research and Development at VectorY therapeutics.
What is Sander Van Deventer's email address?
AeroLeads has found 1 work email signal at @vectorytx.com for Sander Van Deventer at VectorY therapeutics.
What is Sander Van Deventer's phone number?
AeroLeads has found 2 phone signal(s) with area code 135 for Sander Van Deventer at VectorY therapeutics.
Where is Sander Van Deventer based?
Sander Van Deventer is based in Naarden, North Holland, Netherlands while working with VectorY therapeutics.
What companies has Sander Van Deventer worked for?
Sander Van Deventer has worked for Vectory Therapeutics, Vectory, Forbion Capital Partners, Visker Cycles Haarlem, and Porton Biologics Ltd..
How can I contact Sander Van Deventer?
You can use AeroLeads to view verified contact signals for Sander Van Deventer at VectorY therapeutics, including work email, phone, and LinkedIn data when available.
What schools did Sander Van Deventer attend?
Sander Van Deventer holds Md, Phd, Internal Medicine, Gastroenterology from University Of Amsterdam.
What skills is Sander Van Deventer known for?
Sander Van Deventer is listed with skills including Lifesciences, Clinical Development, Biotechnology, Cancer, Translational Medicine, Medical Research, Pharmaceutical Industry, and Monoclonal Antibodies.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial